The use of troglitazone was reported to inhibit MCF-7 tumor growth in triple-negative immunodeficient mice [13] and in DMBA-induced mammary tumorigenesis [32], and administration of a PPARγ ligand (GW7845) also inhibited development of carcinogen-induced breast cancer in rats [33]. Here, PPARG is linked to breast cancer.